NASDAQ:RPHM Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis $1.50 -0.01 (-0.66%) (As of 07/5/2024 08:53 PM ET) Add Compare Share Share Today's Range$1.48▼$1.5450-Day Range$1.50▼$1.9052-Week Range$0.98▼$9.21Volume262,100 shsAverage Volume293,298 shsMarket Capitalization$50.13 millionP/E RatioN/ADividend YieldN/APrice Target$11.01 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Reneo Pharmaceuticals alerts: Email Address Reneo Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingReduce1.88 Rating ScoreUpside/Downside634.2% Upside$11.01 Price TargetShort InterestBearish16.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 2 Articles This WeekInsider TradingAcquiring Shares$637,993 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.83) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.84 out of 5 starsMedical Sector572nd out of 879 stocksPharmaceutical Preparations Industry264th out of 417 stocks 2.9 Analyst's Opinion Consensus RatingReneo Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageReneo Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Reneo Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.50% of the float of Reneo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverReneo Pharmaceuticals has a short interest ratio ("days to cover") of 14.9, which indicates bearish sentiment.Change versus previous monthShort interest in Reneo Pharmaceuticals has recently increased by 2.29%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldReneo Pharmaceuticals does not currently pay a dividend.Dividend GrowthReneo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RPHM. Previous Next 2.0 News and Social Media Coverage News SentimentReneo Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Reneo Pharmaceuticals this week, compared to 1 article on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reneo Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $637,993.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.90% of the stock of Reneo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.98% of the stock of Reneo Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Reneo Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Reneo Pharmaceuticals are expected to grow in the coming year, from ($0.83) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reneo Pharmaceuticals is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reneo Pharmaceuticals is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReneo Pharmaceuticals has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Reneo Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Theo TradeDividends are costing you money!Retirement should be a time of relaxation and financial security, but rising inflation is threatening that idea for many Americans. Traditional income from sources like dividends and bonds are struggling to keep pace with the increasing costs of living, leaving many wondering how to maintain their standard of living. That’s where Ultima Trades can help!Click here to download the eBook now and take control of your financial future. About Reneo Pharmaceuticals Stock (NASDAQ:RPHM)Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.Read More RPHM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPHM Stock News HeadlinesJuly 3, 2024 | americanbankingnews.comReneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Receives Consensus Rating of "Reduce" from BrokeragesJune 26, 2024 | globenewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHMJuly 8, 2024 | Insiders Exposed (Ad)How did they achieve a perfect track record? If you want to learn how A Group of traders Made 917 Trades Without A Single Loss! And How You Could Have Consistently Beat the Market by following them...June 24, 2024 | prnewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHMJune 21, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of ShareholdersJune 21, 2024 | globenewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHMMay 14, 2024 | markets.businessinsider.comMitchell Kapoor’s Hold Rating on Reneo Pharmaceuticals Amid OnKure Merger and Oncology Pipeline PotentialMay 14, 2024 | businesswire.comRENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHMJuly 8, 2024 | Insiders Exposed (Ad)How did they achieve a perfect track record? If you want to learn how A Group of traders Made 917 Trades Without A Single Loss! And How You Could Have Consistently Beat the Market by following them...May 13, 2024 | prnewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Reneo Pharmaceuticals, Inc. - RPHMMay 13, 2024 | finance.yahoo.comReneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares RiseMay 13, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, RPHMMay 13, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Reneo Pharmaceuticals, Inc. has obtained a Fair Price in its Transaction with OnKureMay 13, 2024 | businesswire.comRPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to ShareholdersMay 13, 2024 | markets.businessinsider.comReneo Pharmaceuticals, OnKure To MergeMay 13, 2024 | marketwatch.comReneo Pharmaceuticals Sets Reverse Merger With OnKureMay 13, 2024 | msn.comReneo Pharmaceuticals gains on deal to merge with OnKureMay 13, 2024 | globenewswire.comReneo Pharmaceuticals and OnKure Announce Proposed MergerSee More Headlines Receive RPHM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/08/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RPHM CUSIPN/A CIK1637715 Webreneopharma.com Phone858-283-0280FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$11.01 High Stock Price Target$35.55 Low Stock Price Target$1.50 Potential Upside/Downside+634.2%Consensus RatingReduce Rating Score (0-4)1.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-77,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.76% Return on Assets-60.10% Debt Debt-to-Equity RatioN/A Current Ratio29.83 Quick Ratio29.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.66 per share Price / Book0.56Miscellaneous Outstanding Shares33,421,000Free Float27,439,000Market Cap$50.13 million OptionableOptionable Beta0.19 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Michael G. Grey (Age 71)Founder & Executive Chairman Comp: $100kMr. Gregory J. Flesher (Age 54)President, CEO & Director Comp: $569.7kDr. Alejandro Dorenbaum M.D. (Age 63)Chief Medical Officer Comp: $466.23kMs. Ashley F. Hall J.D. (Age 52)Chief Development Officer Comp: $447.1kMs. Jennifer P. LamSVP of Finance & Administration and Principal Financial & Accounting OfficerMr. Michael P. Cruse (Age 52)Chief Operating Officer Comp: $535.47kMore ExecutivesKey CompetitorsMilestone PharmaceuticalsNASDAQ:MISTCitius PharmaceuticalsNASDAQ:CTXRMenlo TherapeuticsNASDAQ:FOMXPrelude TherapeuticsNASDAQ:PRLDEliem TherapeuticsNASDAQ:ELYMView All CompetitorsInsiders & InstitutionsIkarian Capital LLCSold 432,600 shares on 5/17/2024Ownership: 0.000%Braden Michael LeonardBought 414,281 shares on 5/14/2024Total: $637,992.74 ($1.54/share)Marquette Asset Management LLCBought 73,770 shares on 5/7/2024Ownership: 0.221%Fifth Lane Capital LPSold 7,365 shares on 5/2/2024Ownership: 0.098%BML Capital Management LLCBought 863,684 shares on 4/23/2024Ownership: 6.517%View All Insider TransactionsView All Institutional Transactions RPHM Stock Analysis - Frequently Asked Questions How have RPHM shares performed this year? Reneo Pharmaceuticals' stock was trading at $1.60 at the beginning of 2024. Since then, RPHM stock has decreased by 6.3% and is now trading at $1.50. View the best growth stocks for 2024 here. How were Reneo Pharmaceuticals' earnings last quarter? Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) announced its earnings results on Tuesday, May, 7th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.12. When did Reneo Pharmaceuticals IPO? Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering (IPO) on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO. How do I buy shares of Reneo Pharmaceuticals? Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RPHM) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reneo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reneo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free rphm Stock Alerts